219861-08-2
219861-08-2
Chemical Structure
Escitalopram oxalate
Synonym(s): (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate
- CAS No.: 219861-08-2
- Formula:C22H23FN2O5
- Molecular Weight:414.43
IUPAC Name: (S)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
InChIKey: KTGRHKOEFSJQNS-BDQAORGHSA-N
SMILES: FC1=CC=C([C@@]2(CCCN(C)C)C(C=CC(C#N)=C3)=C3CO2)C=C1.O=C(O)C(O)=O
Biological Activity: Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Escitalopram oxalate | 99.97% | Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Escitalopram oxalate (Standard) | 99.98% | Escitalopram (oxalate) (Standard) is the analytical standard of Escitalopram (oxalate). This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Escitalopram-d6 oxalate | Escitalopram-d6 (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Escitalopram-d4 oxalate | 99.9% | Escitalopram-d4 (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Citalopram oxalate | 99.52% | (R)-Citalopram oxalate, a R-(-) enantiomers of Citalopram (HY-121203), is a serotonin reuptake inhibitor. (R)-Citalopram oxalate is at least 20-fold weaker than S-citalopram (HY-14258) as inhibitor of the 5-HT transporter (SERT). (R)-Citalopram oxalate can be used for research of depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Citalopram | 99.78% | Citalopram is a racemate mixture of the active S(+)-enantiomer (Escitalopram; HY-14258) and R(-)-enantiomer. Citalopram is an orally active selective serotonin reuptake inhibitor (SSRI). Citalopram is an antidepressant and enhances serotoninergic neurotransmission. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Citalopram oxalate | Citalopram oxalate is a serotonin uptake inhibitor that serves as an antidepressant, effectively reducing ethanol uptake in alcoholics and offering a preferable option for depressed patients experiencing tardive dyskinesia compared to tricyclic antidepressants, which may worsen this condition. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Citalopram | R-Citalopram is a drug impurity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Desmethylcitalopram oxalate | (R)-Desmethylcitalopram oxalate is the metabolite of Citalopram (HY-121203). (R)-Desmethylcitalopram oxalate can be used for the research of neurological disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Escitalopram | 99.89% | Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Citalopram hydrobromide | 99.87% | Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI), with blood-brain barrier permeability. Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Desmethylcitalopram oxalate | Desmethylcitalopram oxalate (DCIT oxalate) is a drug impurity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Citalopram hydrochloride | Citalopram hydrochloride is an orally active 5-HT Receptor inhibitor. Citalopram hydrochloride can be used in depression research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53(16): p. 6112-21. [Content Brief]
- [2]. Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10(1): p. 121-8. [Content Brief]
